Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan

Summary To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT). Thirty patients conditioned with 10 Gy single dose TBI (sTBI) and cyc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2011-09, Vol.47 (9), p.915-919
Hauptverfasser: Dahllöf, Göran, Wondimu, Biniyam, Barr-Agholme, Monica, Garming-Legert, Karin, Remberger, Mats, Ringdén, Olle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 919
container_issue 9
container_start_page 915
container_title Oral oncology
container_volume 47
creator Dahllöf, Göran
Wondimu, Biniyam
Barr-Agholme, Monica
Garming-Legert, Karin
Remberger, Mats
Ringdén, Olle
description Summary To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT). Thirty patients conditioned with 10 Gy single dose TBI (sTBI) and cyclophosphamide (Cy) 60 mg/kg for two days and 35 conditioned busulfan (Bu) and Cy as part of the preparative regimen were included in the study. All patients were treated before 13 years of age, and had survived 2–16 years after HSCT. All patients were interviewed according to a standard questionnaire on symptoms of xerostomia and the unstimulated and stimulated whole salivary secretion rate was determined. The stimulated salivary secretion rates were 0.8 ± 0.5 ml/min in sTBI/Cy group compared to 1.1 ± 0.6 ml/min in the Bu/Cy group ( p = 0.01). Dysfunction of either unstimulated or stimulated salivary secretion rates were found in 18/30 (60%) in sTBI/Cy group and 9/35 (26%) in Bu/Cy group ( p < 0.01). There were no differences regarding the number of xerostomia related symptoms in children conditioned with either sTBI/Cy or Bu/Cy. Both unstimulated and stimulated salivary secretion rates were inversely correlated to the total number of complaints of xerostomia. This study shows that children exhibit xerostomia after HSCT irrespective of conditioning with busulfan or sTBI. It is of importance that salivary function is evaluated and that both salivary function as well as the subjective feeling of mouth dryness is evaluated.
doi_str_mv 10.1016/j.oraloncology.2011.06.509
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_542899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837511007226</els_id><sourcerecordid>886601078</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-2694db43ba9eefbe1f75717476a06a76570acdcd4114a94e522f9e7f6615d7253</originalsourceid><addsrcrecordid>eNqNkk-LFDEQxRtR3HX1K0gQxFOPSaaTdHsQZF3_wIIHFbyF6qTazWwmGZO0y-ynN82Mq3jylCL86lXyXjXNM0ZXjDL5crOKCXwMJvr4fb_ilLEVlStBh3vNKevV0FIxrO_Xei37tl8rcdI8ynlDKRVM0IfNCWeq7-SgTpvbb5hiLnHrgLhAzJXzNmEgECwBGz1mg6FkAlPBRHLBLTHoPSkJQt55CAWKi7UxBuuWCi25ceWKlFjAkzHaPXEpgXUHLiYyznn2E4THzYMJfMYnx_Os-fru4sv5h_by0_uP528uWyMoLy2XQ2fHbj3CgDiNyCYlFFOdkkAlKCkUBWON7RjrYOhQcD4NqCYpmbCKi_VZ0x508w3u5lHvkttC2usITh-vrmuFWnS8H4bKvzjwuxR_zJiL3rq8fBoCxjnrvpeSMqr6Sr46kKZ6mBNOd9qM6iUqvdF_R6WXqDSVukZVm58ex8zjFu1d6-9sKvD8CEA24KfquHH5D9cJxlVPK_f2wGE18afDpLNxGAxal9AUbaP7v_e8_kfGeBdcnXyNe8ybOKdQY9JMZ66p_rws17JbjFGqOJfrXyiO0cU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>886601078</pqid></control><display><type>article</type><title>Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Dahllöf, Göran ; Wondimu, Biniyam ; Barr-Agholme, Monica ; Garming-Legert, Karin ; Remberger, Mats ; Ringdén, Olle</creator><creatorcontrib>Dahllöf, Göran ; Wondimu, Biniyam ; Barr-Agholme, Monica ; Garming-Legert, Karin ; Remberger, Mats ; Ringdén, Olle</creatorcontrib><description>Summary To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT). Thirty patients conditioned with 10 Gy single dose TBI (sTBI) and cyclophosphamide (Cy) 60 mg/kg for two days and 35 conditioned busulfan (Bu) and Cy as part of the preparative regimen were included in the study. All patients were treated before 13 years of age, and had survived 2–16 years after HSCT. All patients were interviewed according to a standard questionnaire on symptoms of xerostomia and the unstimulated and stimulated whole salivary secretion rate was determined. The stimulated salivary secretion rates were 0.8 ± 0.5 ml/min in sTBI/Cy group compared to 1.1 ± 0.6 ml/min in the Bu/Cy group ( p = 0.01). Dysfunction of either unstimulated or stimulated salivary secretion rates were found in 18/30 (60%) in sTBI/Cy group and 9/35 (26%) in Bu/Cy group ( p &lt; 0.01). There were no differences regarding the number of xerostomia related symptoms in children conditioned with either sTBI/Cy or Bu/Cy. Both unstimulated and stimulated salivary secretion rates were inversely correlated to the total number of complaints of xerostomia. This study shows that children exhibit xerostomia after HSCT irrespective of conditioning with busulfan or sTBI. It is of importance that salivary function is evaluated and that both salivary function as well as the subjective feeling of mouth dryness is evaluated.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2011.06.509</identifier><identifier>PMID: 21784697</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adolescent ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Busulfan - adverse effects ; Cancer ; Chemotherapy ; Child ; Child, Preschool ; Cyclophosphamide - adverse effects ; Dry mouth ; Female ; Hematology, Oncology and Palliative Medicine ; Hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunosuppressive Agents - adverse effects ; Infant ; Male ; Medical sciences ; Oral ; Otolaryngology ; Otorhinolaryngology. Stomatology ; Pediatric ; Radiation ; Saliva ; Saliva - secretion ; Surveys and Questionnaires ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation Conditioning - adverse effects ; Transplantation Conditioning - methods ; Treatment Outcome ; Tumors ; Whole-Body Irradiation ; Xerostomia - chemically induced</subject><ispartof>Oral oncology, 2011-09, Vol.47 (9), p.915-919</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-2694db43ba9eefbe1f75717476a06a76570acdcd4114a94e522f9e7f6615d7253</citedby><cites>FETCH-LOGICAL-c502t-2694db43ba9eefbe1f75717476a06a76570acdcd4114a94e522f9e7f6615d7253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1368837511007226$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24512780$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21784697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:123173958$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Dahllöf, Göran</creatorcontrib><creatorcontrib>Wondimu, Biniyam</creatorcontrib><creatorcontrib>Barr-Agholme, Monica</creatorcontrib><creatorcontrib>Garming-Legert, Karin</creatorcontrib><creatorcontrib>Remberger, Mats</creatorcontrib><creatorcontrib>Ringdén, Olle</creatorcontrib><title>Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>Summary To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT). Thirty patients conditioned with 10 Gy single dose TBI (sTBI) and cyclophosphamide (Cy) 60 mg/kg for two days and 35 conditioned busulfan (Bu) and Cy as part of the preparative regimen were included in the study. All patients were treated before 13 years of age, and had survived 2–16 years after HSCT. All patients were interviewed according to a standard questionnaire on symptoms of xerostomia and the unstimulated and stimulated whole salivary secretion rate was determined. The stimulated salivary secretion rates were 0.8 ± 0.5 ml/min in sTBI/Cy group compared to 1.1 ± 0.6 ml/min in the Bu/Cy group ( p = 0.01). Dysfunction of either unstimulated or stimulated salivary secretion rates were found in 18/30 (60%) in sTBI/Cy group and 9/35 (26%) in Bu/Cy group ( p &lt; 0.01). There were no differences regarding the number of xerostomia related symptoms in children conditioned with either sTBI/Cy or Bu/Cy. Both unstimulated and stimulated salivary secretion rates were inversely correlated to the total number of complaints of xerostomia. This study shows that children exhibit xerostomia after HSCT irrespective of conditioning with busulfan or sTBI. It is of importance that salivary function is evaluated and that both salivary function as well as the subjective feeling of mouth dryness is evaluated.</description><subject>Adolescent</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Busulfan - adverse effects</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dry mouth</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Infant</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Oral</subject><subject>Otolaryngology</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Pediatric</subject><subject>Radiation</subject><subject>Saliva</subject><subject>Saliva - secretion</subject><subject>Surveys and Questionnaires</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation Conditioning - adverse effects</subject><subject>Transplantation Conditioning - methods</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Whole-Body Irradiation</subject><subject>Xerostomia - chemically induced</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk-LFDEQxRtR3HX1K0gQxFOPSaaTdHsQZF3_wIIHFbyF6qTazWwmGZO0y-ynN82Mq3jylCL86lXyXjXNM0ZXjDL5crOKCXwMJvr4fb_ilLEVlStBh3vNKevV0FIxrO_Xei37tl8rcdI8ynlDKRVM0IfNCWeq7-SgTpvbb5hiLnHrgLhAzJXzNmEgECwBGz1mg6FkAlPBRHLBLTHoPSkJQt55CAWKi7UxBuuWCi25ceWKlFjAkzHaPXEpgXUHLiYyznn2E4THzYMJfMYnx_Os-fru4sv5h_by0_uP528uWyMoLy2XQ2fHbj3CgDiNyCYlFFOdkkAlKCkUBWON7RjrYOhQcD4NqCYpmbCKi_VZ0x508w3u5lHvkttC2usITh-vrmuFWnS8H4bKvzjwuxR_zJiL3rq8fBoCxjnrvpeSMqr6Sr46kKZ6mBNOd9qM6iUqvdF_R6WXqDSVukZVm58ex8zjFu1d6-9sKvD8CEA24KfquHH5D9cJxlVPK_f2wGE18afDpLNxGAxal9AUbaP7v_e8_kfGeBdcnXyNe8ybOKdQY9JMZ66p_rws17JbjFGqOJfrXyiO0cU</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Dahllöf, Göran</creator><creator>Wondimu, Biniyam</creator><creator>Barr-Agholme, Monica</creator><creator>Garming-Legert, Karin</creator><creator>Remberger, Mats</creator><creator>Ringdén, Olle</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20110901</creationdate><title>Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan</title><author>Dahllöf, Göran ; Wondimu, Biniyam ; Barr-Agholme, Monica ; Garming-Legert, Karin ; Remberger, Mats ; Ringdén, Olle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-2694db43ba9eefbe1f75717476a06a76570acdcd4114a94e522f9e7f6615d7253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Busulfan - adverse effects</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dry mouth</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Infant</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Oral</topic><topic>Otolaryngology</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Pediatric</topic><topic>Radiation</topic><topic>Saliva</topic><topic>Saliva - secretion</topic><topic>Surveys and Questionnaires</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation Conditioning - adverse effects</topic><topic>Transplantation Conditioning - methods</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Whole-Body Irradiation</topic><topic>Xerostomia - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dahllöf, Göran</creatorcontrib><creatorcontrib>Wondimu, Biniyam</creatorcontrib><creatorcontrib>Barr-Agholme, Monica</creatorcontrib><creatorcontrib>Garming-Legert, Karin</creatorcontrib><creatorcontrib>Remberger, Mats</creatorcontrib><creatorcontrib>Ringdén, Olle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dahllöf, Göran</au><au>Wondimu, Biniyam</au><au>Barr-Agholme, Monica</au><au>Garming-Legert, Karin</au><au>Remberger, Mats</au><au>Ringdén, Olle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>47</volume><issue>9</issue><spage>915</spage><epage>919</epage><pages>915-919</pages><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>Summary To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT). Thirty patients conditioned with 10 Gy single dose TBI (sTBI) and cyclophosphamide (Cy) 60 mg/kg for two days and 35 conditioned busulfan (Bu) and Cy as part of the preparative regimen were included in the study. All patients were treated before 13 years of age, and had survived 2–16 years after HSCT. All patients were interviewed according to a standard questionnaire on symptoms of xerostomia and the unstimulated and stimulated whole salivary secretion rate was determined. The stimulated salivary secretion rates were 0.8 ± 0.5 ml/min in sTBI/Cy group compared to 1.1 ± 0.6 ml/min in the Bu/Cy group ( p = 0.01). Dysfunction of either unstimulated or stimulated salivary secretion rates were found in 18/30 (60%) in sTBI/Cy group and 9/35 (26%) in Bu/Cy group ( p &lt; 0.01). There were no differences regarding the number of xerostomia related symptoms in children conditioned with either sTBI/Cy or Bu/Cy. Both unstimulated and stimulated salivary secretion rates were inversely correlated to the total number of complaints of xerostomia. This study shows that children exhibit xerostomia after HSCT irrespective of conditioning with busulfan or sTBI. It is of importance that salivary function is evaluated and that both salivary function as well as the subjective feeling of mouth dryness is evaluated.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21784697</pmid><doi>10.1016/j.oraloncology.2011.06.509</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1368-8375
ispartof Oral oncology, 2011-09, Vol.47 (9), p.915-919
issn 1368-8375
1879-0593
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_542899
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adolescent
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Bone marrow, stem cells transplantation. Graft versus host reaction
Busulfan - adverse effects
Cancer
Chemotherapy
Child
Child, Preschool
Cyclophosphamide - adverse effects
Dry mouth
Female
Hematology, Oncology and Palliative Medicine
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immunosuppressive Agents - adverse effects
Infant
Male
Medical sciences
Oral
Otolaryngology
Otorhinolaryngology. Stomatology
Pediatric
Radiation
Saliva
Saliva - secretion
Surveys and Questionnaires
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation Conditioning - adverse effects
Transplantation Conditioning - methods
Treatment Outcome
Tumors
Whole-Body Irradiation
Xerostomia - chemically induced
title Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Xerostomia%20in%20children%20and%20adolescents%20after%20stem%20cell%20transplantation%20conditioned%20with%20total%20body%20irradiation%20or%20busulfan&rft.jtitle=Oral%20oncology&rft.au=Dahll%C3%B6f,%20G%C3%B6ran&rft.date=2011-09-01&rft.volume=47&rft.issue=9&rft.spage=915&rft.epage=919&rft.pages=915-919&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2011.06.509&rft_dat=%3Cproquest_swepu%3E886601078%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=886601078&rft_id=info:pmid/21784697&rft_els_id=S1368837511007226&rfr_iscdi=true